Quotient (QTNT) Upgraded at ValuEngine
ValuEngine upgraded shares of Quotient (NASDAQ:QTNT) from a hold rating to a buy rating in a research report released on Tuesday.
QTNT has been the subject of several other research reports. BidaskClub raised Quotient from a hold rating to a buy rating in a research note on Thursday, June 21st. Zacks Investment Research lowered Quotient from a hold rating to a strong sell rating in a research note on Saturday, June 2nd. Finally, BTIG Research reaffirmed a buy rating and issued a $10.00 target price on shares of Quotient in a research note on Wednesday, May 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Quotient has an average rating of Hold and a consensus target price of $11.50.
Shares of NASDAQ QTNT opened at $7.72 on Tuesday. Quotient has a 12 month low of $2.78 and a 12 month high of $9.02. The company has a quick ratio of 1.59, a current ratio of 2.11 and a debt-to-equity ratio of -3.11. The stock has a market cap of $416.20 million, a PE ratio of -3.82 and a beta of 0.18.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in Quotient in the second quarter worth approximately $517,000. Millennium Management LLC purchased a new stake in Quotient in the second quarter worth approximately $3,699,000. Ardsley Advisory Partners boosted its stake in Quotient by 10.0% in the second quarter. Ardsley Advisory Partners now owns 110,000 shares of the company’s stock worth $883,000 after buying an additional 10,000 shares in the last quarter. Quantum Capital Management purchased a new stake in Quotient in the second quarter worth approximately $429,000. Finally, Paloma Partners Management Co purchased a new stake in Quotient in the second quarter worth approximately $1,240,000. 49.31% of the stock is owned by institutional investors and hedge funds.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Read More: What is a Leveraged Buyout (LBO)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.